echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Eli Lilly's Erbitux new dosing regimen is approved by the U.S. FDA for head and neck cancer and colorectal cancer

    Eli Lilly's Erbitux new dosing regimen is approved by the U.S. FDA for head and neck cancer and colorectal cancer

    • Last Update: 2021-04-18
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Compilenewborn

    Recently, the US FDA approved a new dosage regimen of Eli Lilly’s targeted anticancer drug Erbitux (cetuximab, cetuximab): 500mg/m2 as a 120-minute intravenous infusion, once every 2 weeks (Q2W), for treatment K-Ras wild-type, EGFR-positive metastatic colorectal cancer (mCRC) and squamous cell carcinoma of the head and neck (SCCHN).


    When Erbitux is used as a monotherapy or combination chemotherapy, in addition to the previously approved weekly dosage regimen, the latest approval will provide clinicians and patients with an option of a biweekly dosage regimen.


    The approval is based on population pharmacokinetic (PK) modeling analysis.


    The most common adverse reactions of Erbitux (incidence ≥25%) are skin adverse reactions (including rash, itching, and nail changes), headache, diarrhea, and infection.


    Erbitux’s additional safety and efficacy information, as well as the recommended dosage regimen, have been included in the updated complete Erbitux prescribing information.


    Erbitux is the world's first monoclonal antibody targeting EGFR.


    ——Head and neck cancer: (1) Combined radiotherapy for the initial treatment of patients with locally or regionally advanced SCCHN; (2) Combined platinum regimen and fluorouracil for the treatment of patients with recurrent regional disease or metastatic SCCHN; (3) Used for Treat patients with recurrent or metastatic SCCHN who have progressed after receiving platinum regimens.


    ——Colorectal cancer: used for the treatment of metastatic CRC patients with K-Ras wild-type and EGFR positive expression confirmed by FDA-approved testing products.


    Reference source: FDA approves new dosing regimen for cetuximab

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.